ENSC

Ensysce Biosciences' stock has shown significant volatility over the past six months. As of September 23, 2026, the stock price was $0.4145, experiencing a -3.17% decrease in 24 hours, -8.62% over the last week, but an 11.25% rise over the last month. Annually, the stock decreased by -80.63%. Its 52-week high was $2.75 (September 21, 2026) and its 52-week low was $0.23 (May 13, 2026). Key events include the completion of the final phase of the PF614-MPAR-102 clinical study and receipt of a $5.3 million NIDA funding installment in August 2026, alongside positive topline results for intranasal PF614 abuse potential. In September 2026, the company announced upcoming conference participation, Professor Richard Langford's selection to speak at an FDA Public Hearing on psychedelic drugs, and its advancement of the CRPS program at Painweek 2026. Consensus estimates improved in July 2026, with the 2026 revenue forecast increasing to US$7.30m and EPS to -US$1.53 per share, while April 2026 saw a significant increase in consensus revenue estimates to US$7.70m, despite a downgrade in EPS estimates.